General Information

Stock Quote

ABMD (Common Stock)
Exchange NASDAQ (US Dollar)
Price   $32.79
Change (%)   Stock is Up  1.44  (4.59%)
Volume   1,303,500
Data as of 10/31/14 4:00 PM ET
Minimum 20 minute delay
Refresh quote

Corporate Profile

Abiomed (NASDAQ: ABMD) is a global technology leader focused on RECOVERING HEARTS AND SAVING LIVES.

Abiomed CEO, Chairman, and President, Michael R. Minogue, has focused the company’s efforts on developing ground-breaking technologies designed to assist or replace the life-sustaining pumping function of the failing heart. The Company’s portfolio of products and services offer healthcare professionals an array of choices across a broad clinical spectrum. From the world’s first total replacement heart to the World’s Smallest Heart Pump, 1/100th the size of the heart with rapid and simple insertion, Abiomed is dedicated to finding ways to bring the most advanced and beneficial technology to patients and physicians.

More>>

More »   Recent News

Date Title  
10/30/14

DANVERS, Mass., Oct. 30, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today reports second quarter fiscal 2015 revenue of $51.9 million, an increase of 17% compared to revenue of $44.3 million for the same period of fiscal 2014. Second quarter fiscal 2015 GAAP net income was $3...

10/09/14

DANVERS, Mass., Oct. 9, 2014 (GLOBE NEWSWIRE) -- Abiomed, Inc. (Nasdaq:ABMD) announced today that on Thursday, October 30, 2014, the Company will release financial results for the second quarter of fiscal 2015. The Company will host a conference call to discuss the results on Thursday, October 30, 2014, at 8:00 a.m. ET. Michael R. Minogue, Chairman...

09/18/14

DANVERS, Mass., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced the appointment of Ingrid Goldberg, as Director of Investor Relations.  "We are extremely pleased to have Ingrid on board during a pivotal time of growth and opportunity for the Company," ...

09/16/14

WASHINGTON, Sept. 16, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, today announced clinical trial results from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Percutaneous) System. The clinical trial results demonstrated a survival ...

09/10/14

DANVERS, Mass., Sept. 10, 2014 (GLOBE NEWSWIRE) -- Abiomed Inc. (Nasdaq:ABMD), a leading provider of breakthrough heart support technologies, announced that data from RECOVER RIGHT, an Investigational Device Exemption (IDE) study of the Impella RP™ (Right Peripheral) System, will be released during the scientific sessions at the Cardiovascula...